NASDAQ: PMNPromis Neurosciences Inc Stock
$0.64+0.03 (+4.92%)
Updated Apr 17, 2025
PMN Price
$0.64
Fair Value Price
N/A
Market Cap
$20.76M
52 Week Low
$0.51
52 Week High
$2.37
P/E
5.77x
P/B
1.26x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
$2.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.15
Operating Cash Flow
-$27M
Beta
0.32
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PMN Overview
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PMN's potential to beat the market
- PMN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PMN
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important PMN news, forecast changes, insider trades & much more!
PMN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PMN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PMN is good value based on its earnings relative to its share price (5.77x), compared to the US market average (27.98x)
P/E vs Market Valuation
PMN is good value based on its earnings relative to its share price (5.77x), compared to the US Biotechnology industry average (-177.72x)
P/E vs Industry Valuation
PMN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PMN due diligence checks available for Premium users.
Valuation
PMN fair value
Fair Value of PMN stock based on Discounted Cash Flow (DCF)
Price
$0.64
Fair Value
$0.95
Undervalued by
32.33%
PMN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
5.77x
Industry
-177.72x
Market
27.98x
PMN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PMN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PMN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.26x
Industry
4.05x
PMN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PMN's financial health
Profit margin
Revenue
$0.0
Net Income
-$238.2k
Profit Margin
0%
PMN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.9M
Liabilities
$2.4M
Debt to equity
0.15
PMN's short-term assets ($18.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMN's short-term assets ($18.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.7M
Investing
$0.0
Financing
$470.0k
PMN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PMN vs Biotech Stocks
Promis Neurosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.